GeneDx Holdings Corp.
NASDAQ:WGSMedical - Healthcare Information Services
+$1.52 today
- Market cap
- $1.56B
- Beta
- 1.97
- P/E (TTM)
- -21.8
- EPS (TTM)
- -$2.65
Volume 1.71M
Average 1.28M
WGS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
GeneDx Holdings Corp.NASDAQ: WGS
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue grows, but more slowly than its trailing trend
Q2 FY2026 cost of revenue of $36.2M rose 13.9% year over year, behind the +21.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 6.3% from the prior quarter. Over 3 fiscal years it compounded at -20.9% a year.
Context
- Cost of revenue amounted to 30.3% of revenue in FY2025, down 6.1 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +13.9% toward the trailing-twelve-month pace of +21.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 129.37M USD
- Year-over-year change
- +16.5%
- 4-year CAGR
- -13.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 129.37M | +16.5% |
| FY2024 | 2024-12-31 | 111.05M | -1.3% |
| FY2023 | 2023-12-31 | 112.56M | -56.9% |
| FY2022 | 2022-12-31 | 261.44M | +14.3% |
| FY2021 | 2021-12-31 | 228.8M | — |
Cost of Revenue vs competitors
How WGS compares with its peers on the latest reported figures
- WGS's LTM Jun 2026 cost of revenue of $144.53M is the 4th highest of the 9 companies compared; the peer median is $96.07M.
- Its year-over-year change of +21.5% is the 4th highest of 9, against a peer median of +11.4%.
- Cost of revenue amounts to 31.8% of revenue for WGS, versus a peer median of 48.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $437.4M | +13.2% | +11.4% | 57.1% | |
| LTM Mar 2026 | $249M | -0.1% | +7.1% | 30.0% | |
| LTM Mar 2026 | $196.33M | +9.7% | -8.7% | 61.3% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $144.53M | +21.5% | -20.9% | 31.8% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $114.19M | +39.8% | — | 28.7% |
| LTM Mar 2026 | $77.95M | +24.3% | +30.4% | 22.9% | |
| LTM Mar 2026 | $55.67M | -2.6% | +1.4% | 86.3% | |
| FY2025 | $43.43M | +24.4% | +34.5% | 40.3% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $1.57M | -13.9% | +58.2% | 80.5% |
| Peer median (excluding WGS) | $96.07M | +11.4% | +11.4% | 48.7% | |
Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 212.2M | 234.69M | 202.57M | 305.45M | 427.54M |
| Cost of Revenue | 228.8M | 261.44M | 112.56M | 111.05M | 129.37M |
| Gross Profit | (16.6M) | (26.75M) | 90.01M | 194.4M | 298.17M |
| Gross Margin | -7.8% | -11.4% | 44.4% | 63.6% | 69.7% |
| Research & Development | 105.16M | 86.2M | 58.27M | 45.72M | 72.03M |
| Selling, General & Admin | 318.73M | 338.24M | 194.71M | 168.48M | 239.22M |
| Operating Expenses | 429.55M | 640.9M | 270.6M | 217.61M | 311.25M |
| Depreciation & Amortization | 21.81M | 59.31M | 33.73M | 21.95M | 25.22M |
| EBITDA | (220.75M) | (398.2M) | (136.46M) | (27.64M) | 6.63M |
| EBITDA Margin | -104.0% | -169.7% | -67.4% | -9.1% | 1.5% |
| Operating Income | (446.15M) | (667.65M) | (180.6M) | (23.21M) | (11.8M) |
| Operating Margin | -210.3% | -284.5% | -89.2% | -7.6% | -2.8% |
| Interest Income | 79K | 2.54M | 1.11M | 0 | 0 |
| Interest Expense | 2.84M | 3.21M | 0 | 3.03M | 2.54M |
| Other Income / Expenses | 200.76M | 69.62M | 3.9M | (29.42M) | (9.34M) |
| Income Before Tax | (245.39M) | (598.03M) | (176.69M) | (52.63M) | (21.14M) |
| Pre-Tax Margin | -115.6% | -254.8% | -87.2% | -17.2% | -4.9% |
| Income Tax Expense | 0 | (49.05M) | (926K) | (343K) | (116K) |
| Net Income | (245.39M) | (548.98M) | (175.77M) | (52.29M) | (21.02M) |
| Net Margin | -115.6% | -233.9% | -86.8% | -17.1% | -4.9% |
| EPS (Basic) | (74.93) | (53.63) | (7.23) | (1.94) | (0.73) |
| EPS (Diluted) | (74.93) | (53.63) | (7.23) | (1.94) | (0.73) |
| Weighted Avg Shares | 3.28M | 10.24M | 24.31M | 26.89M | 26.89M |
| Weighted Avg Shares (Diluted) | 3.28M | 10.24M | 24.31M | 26.89M | 26.89M |
GeneDx Holdings Corp.
NASDAQ:WGS
Intrinsic Alpha fair value
Locked
Current Price
$51.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.